Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Lentzsch

Showing results (1-10 of 171) with videos related to

Pageof 18
Sort By:
Blood|February 15, 2014
Bendamustine: the remedy that came in from the coldSuzanne Lentzsch
Seminars in Oncology|January 8, 2017
High-risk smoldering myeloma: Perspective on watchful monitoringSiyang Leng, Suzanne Lentzsch
Current Hematologic Malignancy Reports|October 26, 2013
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategyJordan Schecter, Suzanne Lentzsch
Journal of Oncology Practice|August 11, 2018
Bone-Modifying Agents: Complicated to UseSiyang Leng, Suzanne Lentzsch
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?Rajshekhar Chakraborty, Suzanne Lentzsch
Drug News & Perspectives|November 10, 2007
Treatment of multiple myeloma with SDX-308Rentian Feng, Suzanne Lentzsch
Cancer|September 23, 2020
Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray?Rajshekhar Chakraborty, Suzanne Lentzsch
Pharmacology & Therapeutics|July 17, 2012
The application and biology of immunomodulatory drugs (IMiDs) in cancerBeiqing Pan, Suzanne Lentzsch
Expert Opinion on Emerging Drugs|August 1, 2020
Emerging drugs for the treatment of light chain amyloidosisRajshekhar Chakraborty, Suzanne Lentzsch
Pharmacology & Therapeutics|June 21, 2020
Diagnosis and management of systemic light chain AL amyloidosisDivaya Bhutani, Suzanne Lentzsch
Pageof 18

Showing results (1-10 of 171) with videos related to

Sort By:
Pageof 18
Blood|February 15, 2014
Bendamustine: the remedy that came in from the coldSuzanne Lentzsch
Seminars in Oncology|January 8, 2017
High-risk smoldering myeloma: Perspective on watchful monitoringSiyang Leng, Suzanne Lentzsch
Current Hematologic Malignancy Reports|October 26, 2013
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategyJordan Schecter, Suzanne Lentzsch
Journal of Oncology Practice|August 11, 2018
Bone-Modifying Agents: Complicated to UseSiyang Leng, Suzanne Lentzsch
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?Rajshekhar Chakraborty, Suzanne Lentzsch
Drug News & Perspectives|November 10, 2007
Treatment of multiple myeloma with SDX-308Rentian Feng, Suzanne Lentzsch
Cancer|September 23, 2020
Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray?Rajshekhar Chakraborty, Suzanne Lentzsch
Pharmacology & Therapeutics|July 17, 2012
The application and biology of immunomodulatory drugs (IMiDs) in cancerBeiqing Pan, Suzanne Lentzsch
Expert Opinion on Emerging Drugs|August 1, 2020
Emerging drugs for the treatment of light chain amyloidosisRajshekhar Chakraborty, Suzanne Lentzsch
Pharmacology & Therapeutics|June 21, 2020
Diagnosis and management of systemic light chain AL amyloidosisDivaya Bhutani, Suzanne Lentzsch
Pageof 18